Brief: Bergenbio Q4 Operating Loss NOK 76.4 Million
16/02/2023 06:26
Feb 16 (Reuters) - Bergenbio ASA BGBIO.OL :
* Q4 REVENUE AMOUNTED TO NOK 0.4 MILLION (NOK 0.8 MILLION)
* TOTAL OPERATING EXPENSES FOR Q4 WERE NOK 76.8 MILLION (NOK
68.1
MILLION)
* Q4 OPERATING LOSS CAME TO NOK 76.4 MILLION (NOK 67.3
MILLION)
* CASH AND CASH EQUIVALENTS AMOUNTED TO NOK 150.8 MILLION AT
END
OF DECEMBER 2022
Source text: https://mfn.se/cis/a/bergenbio/bergenbio-asa-bergenbio-reports-fourth-quarter-2022-financial-results-and-provides-business-update-a60aecd4
Further company coverage: BGBIO.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Oncoinvent ASA
See all newsBrief: Oncoinvent To Raise Up To NOK 140 Million In Private Placement
Brief: Oncoinvent H1 Operating Loss NOK 69 Mln
Brief: Oncoinvent Secures New Patent Expanding Protection For Radspherin
Brief: Oncoinvent's Shares To Be Consolidated In Ratio Of 100:1
Brief: Oncoinvent To Increase Share Capital In Connection With Settlement Of Underwriting Fee